Clinical trial
Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in…
NCT00111423 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00111423 |
|---|---|
| Title | Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA) |
| Official title | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI) in Subjects With Rheumatoid Arthritis (RA) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Pegsunercept (PEG sTNF-RI) |
| Enrollment | 216 |
| Start date | Aug 1, 2002 |
| First posted | May 23, 2005 |
| Last update posted | Mar 6, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: